Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
ID | DOID:3498 |
Name | pancreatic ductal adenocarcinoma |
Definition | A pancreatic adenocarcinoma that derives_from pancreatic duct cells. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer pancreatic cancer pancreatic carcinoma pancreatic adenocarcinoma pancreatic ductal adenocarcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
Unknown unknown | Lestaurtinib | pancreatic ductal adenocarcinoma | not applicable | detail... |
CDH1 over exp | Erlotinib + Selumetinib | pancreatic ductal adenocarcinoma | sensitive | detail... |
Unknown unknown | PI-3065 | pancreatic ductal adenocarcinoma | not applicable | detail... |
Unknown unknown | Gemcitabine + MN58b | pancreatic ductal adenocarcinoma | not applicable | detail... |
Unknown unknown | Fluorouracil + MN58b | pancreatic ductal adenocarcinoma | not applicable | detail... |
Unknown unknown | MN58b + Oxaliplatin | pancreatic ductal adenocarcinoma | not applicable | detail... |
Unknown unknown | Gemcitabine + Masitinib | pancreatic ductal adenocarcinoma | not applicable | detail... |
Unknown unknown | MitoMet-10 | pancreatic ductal adenocarcinoma | not applicable | detail... |
Unknown unknown | MitoMet-10 + Radiotherapy | pancreatic ductal adenocarcinoma | not applicable | detail... |
Unknown unknown | JQ1 | pancreatic ductal adenocarcinoma | not applicable | detail... |
Unknown unknown | Gemcitabine + JQ1 | pancreatic ductal adenocarcinoma | not applicable | detail... |
EML4 - ALK CDKN2A del FGFR1 T141R SMAD4 Q83* | Crizotinib | pancreatic ductal adenocarcinoma | predicted - resistant | detail... |
EML4 - ALK CDKN2A del FGFR1 T141R SMAD4 Q83* | Alectinib | pancreatic ductal adenocarcinoma | predicted - sensitive | detail... |
Unknown unknown | Gemcitabine + Pelareorep | pancreatic ductal adenocarcinoma | not applicable | detail... |
Unknown unknown | Selumetinib + SHP099 | pancreatic ductal adenocarcinoma | not applicable | detail... |
BRAF N486_P490del | Trametinib | pancreatic ductal adenocarcinoma | predicted - sensitive | detail... |
Unknown unknown | Arsenic trioxide + JQ1 | pancreatic ductal adenocarcinoma | not applicable | detail... |
Unknown unknown | Arsenic trioxide + Chloroquine + JQ1 | pancreatic ductal adenocarcinoma | not applicable | detail... |
Unknown unknown | Cisplatin + Gemcitabine | pancreatic ductal adenocarcinoma | not applicable | detail... |
Unknown unknown | LMB-100 + Nab-paclitaxel | pancreatic ductal adenocarcinoma | not applicable | detail... |
Unknown unknown | Atezolizumab + BKT140 | pancreatic ductal adenocarcinoma | no benefit | detail... |
Unknown unknown | Dinaciclib | pancreatic ductal adenocarcinoma | not applicable | detail... |
Unknown unknown | Fluorouracil + Oxaliplatin + Veliparib | pancreatic ductal adenocarcinoma | not applicable | detail... |
ATM R3008C | Fluorouracil + Oxaliplatin + Veliparib | pancreatic ductal adenocarcinoma | no benefit | detail... |
ATM T2333Nfs*40 | Fluorouracil + Oxaliplatin + Veliparib | pancreatic ductal adenocarcinoma | no benefit | detail... |
Unknown unknown | Gemcitabine + Nab-paclitaxel + PEGPH20 | pancreatic ductal adenocarcinoma | no benefit | detail... |
Unknown unknown | Gemcitabine + Ipafricept + Nab-paclitaxel | pancreatic ductal adenocarcinoma | not applicable | detail... |
Unknown unknown | Gemcitabine + Nab-paclitaxel + Vantictumab | pancreatic ductal adenocarcinoma | not applicable | detail... |
Unknown unknown | Gemcitabine + Nab-paclitaxel + PF-04136309 | pancreatic ductal adenocarcinoma | no benefit | detail... |
Unknown unknown | Gemcitabine + Nab-paclitaxel + Tarextumab | pancreatic ductal adenocarcinoma | no benefit | detail... |
Unknown unknown | Gemcitabine + MM-141 + Nab-paclitaxel | pancreatic ductal adenocarcinoma | no benefit | detail... |
Unknown unknown | Gemcitabine + Nab-paclitaxel + Necuparanib | pancreatic ductal adenocarcinoma | no benefit | detail... |
Unknown unknown | Hydroxychloroquine + Trametinib | pancreatic ductal adenocarcinoma | not applicable | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01647828 | Phase Ib/II | Nab-paclitaxel Gemcitabine Tarextumab | A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer | Completed | USA | 0 |
NCT02042378 | Phase II | Rucaparib | A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation | Completed | USA | 1 |
NCT02101021 | Phase II | Gemcitabine + Nab-paclitaxel Momelotinib | Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma | Terminated | USA | 0 |
NCT02109445 | Phase II | Gemcitabine + Nab-paclitaxel PF-03084014 | Study Of PF-03084014 In Combination With Gemcitabine And Nab-Paclitaxel In Patients With Metastatic Pancreatic Adenocarcinoma Not Previously Treated With Anticancer Therapies | Terminated | USA | 0 |
NCT02241187 | Phase I | Cetuximab + PEGPH20 | Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection | Completed | USA | 0 |
NCT02259114 | Phase I | Birabresib | A Phase IB Trial With OTX015, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Selected Advanced Solid Tumors | Completed | 0 | |
NCT02289898 | Phase II | Demcizumab + Gemcitabine + Nab-paclitaxel | Study of Gemcitabine, Abraxane Plus Placebo Versus Gemcitabine, Abraxane Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma | Completed | USA | CAN | 4 |
NCT02362048 | Phase II | Acalabrutinib Pembrolizumab | ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer | Completed | USA | 0 |
NCT02501902 | Phase I | Nab-paclitaxel + Palbociclib | Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC | Completed | USA | 1 |
NCT02559492 | Phase I | Epacadostat + Itacitinib Itacitinib + Parsaclisib | INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors | Terminated | USA | 0 |
NCT02583477 | Phase Ib/II | AZD5069 + Durvalumab Durvalumab + Gemcitabine + Nab-paclitaxel | Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma | Completed | USA | 1 |
NCT02600949 | Phase I | Pembrolizumab | Peptide Vaccine in Advanced Pancreatic Ductal Adenocarcinoma or Colorectal Adenocarcinoma | Recruiting | USA | 0 |
NCT02672917 | Phase I | MVT-5873 | Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies | Recruiting | USA | 0 |
NCT02705196 | Phase Ib/II | Atezolizumab + Gemcitabine + LOAd703 + Nab-paclitaxel Gemcitabine + LOAd703 + Nab-paclitaxel | LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer | Recruiting | USA | 0 |
NCT02732938 | Phase I | Gemcitabine + Nab-paclitaxel + PF-04136309 | Ph1b/2 Study of PF-04136309 in Combination With Gem/Nab-P in First-line Metastatic Pancreatic Patients (CCR2i) | Terminated | USA | 0 |
NCT02754726 | Phase II | Cisplatin + Gemcitabine + Nab-paclitaxel + Nivolumab + Paricalcitol | Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma | Recruiting | USA | 0 |
NCT02810418 | Phase Ib/II | LMB-100 LMB-100 + Nab-paclitaxel | Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors | Active, not recruiting | USA | 0 |
NCT02857270 | Phase I | LY3214996 Gemcitabine + LY3214996 + Nab-paclitaxel LY3214996 + Midazolam Abemaciclib + LY3214996 | A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer | Recruiting | USA | 3 |
NCT02879318 | Phase II | Gemcitabine + Nab-paclitaxel Durvalumab + Tremelimumab | Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Pancreatic Adenocarcinoma | Active, not recruiting | CAN | 0 |
NCT02880371 | Phase Ib/II | ARRY-382 + Pembrolizumab | A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT02921022 | Phase 0 | Gemcitabine + Nab-paclitaxel + PEGPH20 | Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma | Active, not recruiting | USA | 0 |
NCT02942095 | Phase I | Erlotinib + Ixazomib | Study of Ixazomib and Erlotinib in Solid Tumors | Active, not recruiting | USA | 0 |
NCT02978547 | Phase II | Metformin | The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma (Metformin 001) | Unknown status | CAN | 0 |
NCT02981342 | Phase II | Capecitabine Abemaciclib Gemcitabine Abemaciclib + LY3023414 Abemaciclib + Galunisertib | A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma | Completed | USA | 7 |
NCT02993731 | Phase III | Gemcitabine + Nab-paclitaxel + Napabucasin Gemcitabine + Nab-paclitaxel | A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma (CanStem111P) | Completed | USA | CAN | 18 |
NCT03038477 | Phase II | Durvalumab | A Study of Durvalumab in Patients With Borderline Resectable Pancreas Adenocarcinoma Following Neoadjuvant Therapy and Successful Surgical Resection | Withdrawn | USA | 0 |
NCT03076372 | Phase I | MM-310 | A Study Evaluating MM-310 in Patients With Solid Tumors | Unknown status | USA | 0 |
NCT03118349 | Phase I | MVT-1075 + MVT-5873 | Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as Radioimmunotherapy | Active, not recruiting | USA | 0 |
NCT03193190 | Phase Ib/II | Atezolizumab + BKT140 Fluorouracil + Gemcitabine + Leucovorin + Nab-paclitaxel + Oxaliplatin + Pembrolizumab Atezolizumab + PEGPH20 Atezolizumab + Cobimetinib | A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | Recruiting | USA | 4 |
NCT03264404 | Phase II | Azacitidine + Pembrolizumab | Azacitidine and Pembrolizumab in Pancreatic Cancer | Recruiting | USA | 0 |
NCT03412799 | Phase I | Gemcitabine + Nab-paclitaxel + SBP-101 | Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer | Recruiting | USA | 1 |
NCT03415126 | Phase I | ASN007 | A Study of ASN007 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
NCT03415854 | Phase II | Cisplatin + Gemcitabine + Nab-paclitaxel + Paricalcitol | Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) (NABPLAGEMD) | Active, not recruiting | USA | 0 |
NCT03425279 | Phase Ib/II | CAB-AXL-ADC | CAB-AXL-ADC Safety and Efficacy Study in Patients With Solid Tumors | Recruiting | USA | 0 |
NCT03432676 | Phase II | Epacadostat + Pembrolizumab | Study of IDO-1 Inhibitor Epacadostat in Combination With Pembrolizumab in Advanced Pancreatic Cancer With Chromosomal Instability/ Homologous Recombination Repair Deficiency (HRD) | Withdrawn | 0 | |
NCT03435250 | Phase I | AG-270 + Docetaxel AG-270 + Gemcitabine + Nab-paclitaxel AG-270 | Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss | Recruiting | USA | 2 |
NCT03450018 | Phase Ib/II | Gemcitabine + SLC-0111 | A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX (SLC-0111-17-01) | Recruiting | CAN | 0 |
NCT03496662 | Phase Ib/II | Nivolumab BMS-813160 + Gemcitabine + Nab-paclitaxel Gemcitabine + Nab-paclitaxel BMS-813160 + Gemcitabine + Nab-paclitaxel + Nivolumab | BMS-813160 With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) | Recruiting | USA | 0 |
NCT03592888 | Phase I | mDC3/8-KRAS vaccine | DC Vaccine in Pancreatic Cancer | Recruiting | USA | 0 |
NCT03608631 | Phase I | iExosomes | iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation | Not yet recruiting | USA | 0 |
NCT03610490 | Phase II | Aldesleukin + Cyclophosphamide + Fludarabine + MDA autologous tumor-infiltrating lymphocytes | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma | Recruiting | USA | 0 |
NCT03634332 | Phase II | PEGPH20 + Pembrolizumab | Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC | Recruiting | USA | 0 |
NCT03637491 | Phase II | Avelumab + Binimetinib + Talazoparib Avelumab + Binimetinib | A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors | Recruiting | USA | 2 |
NCT03681951 | Phase Ib/II | GSK3145095 GSK3145095 + Pembrolizumab | First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors | Terminated | USA | 0 |
NCT03682289 | Phase II | AZD6738 + Olaparib Olaparib | Phase II Trial of AZD6738 Alone and in Combination With Olaparib | Recruiting | USA | 0 |
NCT03727880 | Phase II | Defactinib + Pembrolizumab Pembrolizumab | Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma | Recruiting | USA | 0 |
NCT03733990 | Phase Ib/II | FP-1305 | A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) | Recruiting | USA | 5 |
NCT03811652 | Phase I | MEDI7247 | A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors | Completed | USA | CAN | 0 |
NCT03953235 | Phase Ib/II | GRT-C903 + GRT-R904 + Ipilimumab + Nivolumab | A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens | Recruiting | USA | 0 |
NCT03979066 | Phase II | Atezolizumab Atezolizumab + PEGPH20 | Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma (NEOiPANC) | Terminated | USA | 0 |
NCT04042480 | Phase I | SGN-CD228A | A Study of SGN-CD228A in Advanced Solid Tumors | Recruiting | USA | 4 |
NCT04111172 | Phase II | Ad5.F35-hGCC-PADRE | Phase 2A Study of Ad5.F35-hGCC-PADRE in Gastrointestinal Malignancies | Recruiting | USA | 0 |
NCT04161755 | Phase I | Atezolizumab + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin + RO7198457 | Study of Personalized Tumor Vaccines (PCVs) and a PD-L1 Blocker in Patients With Pancreatic Cancer That Can be Treated With Surgery | Recruiting | USA | 0 |
NCT04262388 | Phase II | Durvalumab + Oleclumab | A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation (DOME) | Withdrawn | CAN | 0 |
NCT04477343 | Phase I | Nivolumab + SX-682 | A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | Recruiting | USA | 0 |
NCT04493060 | Phase II | Dostarlimab + Niraparib | Niraparib and Dostarlimab for Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer | Recruiting | USA | 0 |
NCT04536077 | Phase II | CDX-1140 + CDX-301 CDX-1140 | Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients | Not yet recruiting | USA | 0 |
NCT04581343 | Phase I | Canakinumab + Gemcitabine + Nab-paclitaxel + Spartalizumab | A Phase 1B Study of Canakinumab, Spartalizumab, Nab-paclitaxel, and Gemcitabine in Metastatic PC Patients (PanCAN-SR1) | Recruiting | USA | 0 |
NCT04704154 | Phase II | Nivolumab + Regorafenib | A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors | Recruiting | USA | 7 |
NCT04753879 | Phase II | Olaparib + Pembrolizumab Capecitabine + Cisplatin + Gemcitabine + Irinotecan + Nab-paclitaxel | Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer. | Not yet recruiting | USA | 0 |